109 results
Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Thumbnail

D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Thumbnail

000766 - Clonal mast cell disorders, allergy to hymenoptera venom and venom immunotherapy – our experience

Thumbnail

001066 - The Impact of Bee Sting Experiences on Quality of Life and Perceived Health Threat in Korean Beekeepers with Bee Venom Allergy

Thumbnail

100085 - Code Anaphylaxis: enhancing the management of Hymenoptera venom anaphylaxis

Thumbnail

D1.162 - Selecting the right immunotherapy for Vespa velutina nigrithorax anaphylaxis: does one treatment fits all?

Thumbnail

D2.75 - Allergy to insects in children

Thumbnail

D3.423 - Cross-Reactivity Among Hymenoptera Venoms: A Case Study on Apis, Vespula, and Polistes Allergens

Thumbnail

D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives

Thumbnail

D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy

Thumbnail

D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts

Thumbnail

D3.424 - Long-term efficacy and re-sting outcomes following venom immunotherapy discontinuation: A 978-patient analysis